drugset / Trial / NCT00890591

Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

NCT00890591

Phase 4 Completed 144 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine.

Timeline

Start
2006-08
Primary completion
2007-06
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified
Subject Hydrochlorothiazide Unknown
Subject Olmesartan medoxomil Unknown